Effect of traditional Chinese medicine syndrome differentiation and treatment combined with Icotinib on survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma

Liping SHEN; Lingshuang LIU; Yi JIANG; Aiqin GU

doi:10.16305/j.1007-1334.2021.2011071

您当前的位置：

首页 >

文章列表页 >

Effect of traditional Chinese medicine syndrome differentiation and treatment combined with Icotinib on survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma

更新时间：2022-08-03

- Effect of traditional Chinese medicine syndrome differentiation and treatment combined with Icotinib on survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma
- Shanghai Journal of Traditional Chinese Medicine Vol. 55, Issue 4, Pages: 40-44(2021)
- 作者机构：
  
  1.上海中医药大学附属龙华医院肿瘤六科（上海　200032）
  2.上海交通大学附属胸科医院呼吸内科（上海　200030）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2021.2011071
  CLC：
扫描看全文
Liping SHEN, Lingshuang LIU, Yi JIANG, et al. Effect of traditional Chinese medicine syndrome differentiation and treatment combined with Icotinib on survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma. [J]. Shanghai Journal of Traditional Chinese Medicine 55(4):40-44(2021)
DOI：

Liping SHEN, Lingshuang LIU, Yi JIANG, et al. Effect of traditional Chinese medicine syndrome differentiation and treatment combined with Icotinib on survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma. [J]. Shanghai Journal of Traditional Chinese Medicine 55(4):40-44(2021) DOI： 10.16305/j.1007-1334.2021.2011071.

摘要

目的,2,观察中医辨证治疗联合埃克替尼对表皮生长因子受体（EGFR）突变老年晚期肺腺癌患者生存期的影响。,方法,2,将74例EGFR突变老年晚期肺腺癌患者随机分为治疗组和对照组，每组37例，对照组单用埃克替尼治疗，治疗组在此基础上加用中医辨证汤剂。观察治疗后疾病发生进展及死亡的时间，计算中位疾病无进展生存期（mPFS）及中位生存期（MST）。,结果,2,①随访至2020年7月30日，治疗组脱落1例、对照组脱落2例，共纳入71例病例进行统计，其中治疗组36例、对照组35例。②治疗组、对照组mPFS分别为15.40个月、13.07个月，组间差异有统计学意义（,P,=0.024，,HR,=0.575）。③治疗组、对照组的MST分别为29.90个月、25.07个月，组间差异有统计学意义（,P,=0.045，,HR,=0.580）。④多因素分析结果显示，联合中医药治疗、一线埃克替尼治疗、曾经接受肺癌根治术、较少的合并症是影响EGFR突变老年晚期肺腺癌患者远期生存预后的独立保护因素（,P,<,0.05）。,结论,2,中医辨证治疗联合埃克替尼可延长EGFR突变老年晚期肺腺癌患者的无进展生存期及总生存期，一线埃克替尼治疗阶段、肺癌根治术及较少的合并症也有利于老年晚期肺腺癌患者的远期生存预后。

Abstract

Objective,2,To observe the effect of traditional Chinese medicine (TCM) syndrome differentiation and treatment combined with Icotinib on the overall survival of elderly patients with advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation.,Methods,2,A total of 74 elderly patients with EGFR-mutant advanced lung adenocarcinoma were randomly divided into treatment group (,n,=37) and control group (,n,=37). The control group was administered with Icotinib alone, and the treatment group was additionally administered with TCM decoction based on syndrome differentiation besides Icotinib. The time of disease progression and death after treatment in the two groups was observed, and the median progression-free survival (mPFS) time and median survival (MST) time were calculated.,Results,2,①As of July 30,th, 2020, 71 patients were finally included after follow-ups for statistical analysis with one drop-out case in the treatment group (,n,=36) and two drop-out cases in the control group (,n,=35). ②The mPFS of the treatment group and the control group were 15.40 months and 13.07 months respectively, with significant difference between the two groups (,P,=0.024,HR,=0.575); ③The MST of the treatment group and the control group were 29.90 months and 25.07 months respectively, with significant difference between the two groups (,P,=0.045,HR,=0.580). ④Multivariate analysis showed that combined treatment of traditional Chinese medicine, first-line Icotinib treatment, previous radical resection of lung cancer, and fewer comorbidities were independent protective factors affecting the long-term survival and prognosis of elderly patients with EGFR-mutant advanced lung adenocarcinoma (,P,<,0.05).,Conclusion,2,TCM syndrome differentiation and treatment combined with Icotinib can prolong the progression-free survival and overall survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma. The first-line Icotinib treatment stage, radical resection of lung cancer and fewer comorbidities are also conducive to the long-term survival prognosis of elderly patients with advanced lung adenocarcinoma.

关键词

肺腺癌非小细胞肺癌晚期埃克替尼生存期预后中医药疗法

Keywords

lung adenocarcinomanon-small cell lung canceradvancedIcotinibsurvivalprognosistraditional Chinese medicine therapy

references

OWONIKOKO T K, RAGIN C C, BELANI C P, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database[J]. J Clin Oncol, 2007, 25(35): 5570-5577.

DAVIDOFF A J, TANG M, SEAL B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13): 2191-2197.

SHI J F, WANG L, WU N, etal. Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey[J/OL]. Lung Cancer, 2019, 128: 91-100[2020-11-10]. https://pubmed.ncbi.nlm.nih.gov/30642458/https://pubmed.ncbi.nlm.nih.gov/30642458/.

沈丽萍，刘苓霜，姜怡，等. 扶正解毒法联合盐酸埃克替尼治疗老年晚期肺腺癌的临床研究[J]. 天津中医药大学学报，2019, 38(5): 445-451.

支修益，石远凯，于金明. 中国原发性肺癌诊疗规范（2015年版）[J]. 中华肿瘤杂志，2015, 37(1): 67-78.

DETTERBECK F C, BOFFA D J, TANOUE L T. The new lung cancer staging system[J]. Chest, 2009, 136(1): 6-8.

国家药品监督管理局. 中药新药临床研究指导原则（试行）[M]. 北京：中国医药科技出版社，2002: 216-221.

GOTO K, NISHIO M, YAMAMOTO N, et al. A prospective, phase Ⅱ, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)[J]. Lung Cancer, 2013, 82(1): 109-114.

KUWAKO T, IMAI H, MASUDA T, et al. First-line gefitinib treatment in elderly patients （aged≥75 years） with non-small cell lung cancer harboring EGFR mutations[J]. Cancer Chemother Pharmacol, 2015, 76(4): 761-769.

石远凯，孙燕，丁翠敏，等. 中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）[J].中国肺癌杂志，2016, 19(7): 489-493.

任一理，生金，周小芸，等. 埃克替尼治疗表皮生长因子受体敏感突变型高龄晚期非小细胞肺癌患者的临床疗效[J]. 中华肿瘤杂志，2019, 41(2): 152-153.

IMAIA H, YAMADAB Y, SUGIYAMAC T, et al. Clinical impact of post-progression survival on overall survival in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line EGFR tyrosine kinase inhibitors[J]. Chemotherapy, 2018, 63(3): 181-190.

谢泽萍，文凤，李纬，等. 免疫衰老在肿瘤及其免疫疗法中的研究进展[J]. 中国肿瘤，2019, 28(12): 934-940.

刘嘉湘，田建辉. 传承中医药学术精华，促进肿瘤学创新发展[J]. 上海中医药杂志，2020, 54(7): 29-33.

刘苓霜，张朋，姜怡，等. 中医扶正法治疗肺癌的临床疗效及其对机体的免疫调节作用[J]. 自然杂志，2019, 41(4): 281-286.

辛晓丽，姜怡，沈丽萍，等. 中医药辅助治疗600例老年非小细胞肺癌患者的生存分析[J]. 中医杂志，2019, 60(1): 31-35.

李爱武，周彩存，徐建芳. 年龄与并发症对老年晚期非小细胞肺癌患者治疗和生存期的影响[J]. 肿瘤，2008, 28(7): 596-600.

刘苓霜，姜怡，沈丽萍，等. 103例老年晚期非小细胞肺癌中医药治疗的回顾性研究[J]. 上海中医药大学学报，2011, 25(6): 26-29.

Views

204

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery

Efficacy and safety of Yiqi Yangyin Jiedu regimen plus anlotinib in the treatment of advanced non⁃small cell lung cancer

Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery

Clinical analysis of PD-1 monoclonal antibody supplemented with traditional Chinese medicine in the treatment of non-small cell lung cancer

Effects of Chaihu Shugan Powder on AMPK/SIRT3 signaling pathway in rats with functional dyspepsia

Related Author

No data

Related Institution

Department of Integrative Medicine， Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Department of Oncology， Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology I， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Clinical Immunology， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

⁰